A combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) has demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with standard-of-care chemotherapy plus pembrolizumab in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer, according to topline results from the phase III ASCENT-04/KEYNOTE-D19 trial.
Breast Cancers Today
Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.
Advertisement
Latest News
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Expert Interviews
Advertisement
Editorial Board
Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute
Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego
Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center
Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute
Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.